Status:
COMPLETED
Insulin Glulisine, Insulin Lispro and Insulin Glargine in Type 1 or 2 Diabetes Mellitus
Lead Sponsor:
Sanofi
Conditions:
Diabetes Mellitus
Eligibility:
All Genders
18-70 years
Phase:
PHASE3
Brief Summary
Primary: * To compare the efficacy and safety of Insulin Glulisine to Insulin Lispro in subjects with type 1 or type 2 diabetes mellitus. * To compare the frequency of hypoglycemia of Insulin Glulisi...
Eligibility Criteria
Inclusion
- Type 1 or type 2 diabetic patients
- Measure HbA1c 6.5% to 11.0% at visit 1
- More than 3 months of continuous insulin treatment immediately prior to study entry
Exclusion
- Pregnant women
- The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Key Trial Info
Start Date :
January 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
485 Patients enrolled
Trial Details
Trial ID
NCT00467376
Start Date
January 1 2007
Last Update
September 15 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sanofi-Aventis
Beijing, China